Search tips
Search criteria

Results 1-25 (764634)

Clipboard (0)

Related Articles

1.  A comparative study of efficacy of Tugaksheeree [Curcuma angustifolia Roxb. and Maranta arundinacea Linn.] in management of Amlapitta 
Ayu  2010;31(4):482-486.
Amlapitta is a disease caused by increase of Amla Guna of Pitta. Starch obtained from the rhizomes of two plants viz., Curcuma angustifolia Roxb. (Fam. Zingiberaceae) and Maranta arundinacea Linn. (Fam. Marantaceae) are used as Tugaksheeree. In the present clinical study, the efficacy of Tugaksheeree was studied on 67 patients of Amlapitta. A 0 total of 84 patients suffering from Amlapitta were selected from the O.P.D. and I.P.D. sections in the department of Dravyaguna, I.P.G.T. and R.A., Hospital, Jamnagar, and were randomly divided into two groups. Thirty four patients completed the treatment course in Group I, and 33 patients completed the treatment course in Group II. The efficacy of drug Tugaksheeree was studied through internal administration of the starches of C. angustifolia Roxb. (Fam. Zingiberaceae) in Group I and M. arundinacea Linn. (Fam. Marantaceae) in Group II with the dose of 4 g TID with water for 30 days. Both the drugs were found highly effective in treating Amlapitta. They significantly relieved the cardinal symptoms viz., Avipaka, Tikta-amlodgara, Daha, Shoola, Chhardi and the associated symptoms viz., Aruchi, Gaurava, Udaradhmana, Antrakujana, Vit bheda, Shiroruja, Angasada, and Trit. Statistically significant increase in body weight was noticed in both the groups. This may be because the drugs corrected the Agni and acted as Brihmana and Dhatupushtikara. Both the drugs did not produce any side effects. Therefore, both these drugs (C. angustifolia Roxb. and M. arundinacea Linn.) can be used as substitutes for each other.
PMCID: PMC3202266  PMID: 22048544
Tugaksheeree; Curcuma angustifolia Roxb. and Maranta arundinacea Linn. Starch; Amlapitta
2.  A comparative clinical trial of Chincha kshara and Kadali kshara on Amlapitta 
Ayu  2011;32(4):494-499.
A clinical trial was carried out on 30 patients of Amlapitta aged between 20 to 35 years with complaints of Avipaka, hrit-kanthadaha, tikta-amlodgara, utklesa, udarasula, adhmana and aruchi, who were registered from OPD and IPD of Gopabandhu Ayurveda Mahavidyalaya, Puri. They were equally divided into three groups Chincha kshara, Kadali kshara and placebo (who were administered with fresh wheat powder) for 30 days in a dose of 500 mg thrice daily with water. Investigations was done in order to exclude upper gastrointestinal tract ulcer, carcinoma in stomach, cholecystitis, carcinoma gall bladder, and heart diseases. The clinical assessments were carried out on the 30th day by subjective and objective parameters and it was inferred that both Chincha kshara and Kadali kshara were effective and reduced the symptoms of amlapitta. Chincha kshara was found to be more effective than Kadali kshara. The study shows the effect of Chincha and Kadali kshara which led to cure in 4(40%) and 3(30%) patients respectively, and maximum improvement in 4(40%) and 5(50%) patients affected with amlapitta disease, respectively. No untoward effect was noticed due to administration of ksharas during the clinical trial period.
PMCID: PMC3361924  PMID: 22661843
Adhmana; Amlapitta; Chincha kshara; Kadali kshara; Udarasula
3.  A comparative clinical study of Shatapatrayadi churna tablet and Patoladi yoga in the management of Amlapitta 
Ayu  2011;32(3):361-364.
Amlapitta is a very common disease caused by Vidagdha Pitta with features such as Amlodgara, Hrid Kantha Daha, and Avipaka. This is a burning problem of the society. Irregular and improper food habits, and busy stressful lifestyle is one of the main culprit. Amlapitta is the GI disorder described in Ayurvedic texts that closely resembles with Gastritis in modern science. In chronic stage, it may lead to ulcerative conditions. In this study, total 41 patients were registered and were randomly divided into two groups. In group A, Shatapatrayadi churna tablet and in group B Patoladi Yoga tablet were given for 1 month. The Nidana, signs, and symptoms were observed carefully to get idea about the Samprapti of the disease. The effect of Patoladi Yoga on Roga Bala is 65.79%, 62.11% on Agni Bala, and 63.35% on Deha and Chetasa bala. The overall relief was 63.75%. The effect of Shatapatrayadi tablet on Roga Bala was 71.94%, 73.15% on Agni Bala, and 77.68% on Deha and Chetas Bala. The overall relief was 74.25%.
PMCID: PMC3326883  PMID: 22529651
Amlapitta; gastritis; Patoladi yoga; Shatapatrayadi churna
4.  Antiulcer activity of Amlapitta Mishran suspension in rats: A pilot study 
Ancient Science of Life  2012;32(2):112-115.
Amlapitta Mishran suspension is a poly herbal ayurvedic formulation, which has been traditionally used for acidity and gastric ulcers.
The aim of this study is to evaluate the antiulcer activity of Amlapitta Mishran on non-steroidal anti-inflammatory drugs (NSAID's) -induced ulcers in the rat model.
Subjects and Methods:
The antiulcer activity of Amlapitta Mishran was investigated on indomethacin (100 mg/kg) NSAID's induced ulcers in rats. Effect of two different doses of Amlapitta Mishran was studied by calculating the total number of ulcers, ulcer index and percentage inhibition.
Statistical Analysis Used:
Data was analyzed by the Student's t-test (P < 0.05).
Amlapitta Mishran treated rats have shown significant (P < 0.0001) decrease in the total number of ulcers and ulcer index and significant increase in % inhibition of ulcers as compared with positive control group.
The results indicate that Amlapitta Mishran has showed a dose dependent antiulcer activity in experimental animals and confirms ayurvedic use of Amlapitta Mishran in gastric ulcers.
PMCID: PMC3807954  PMID: 24167338
Antiulcer activity; cyclooxygenase; gastric ulcers; indomethacin
5.  PA01.01. 22. Gradation method - A new approach for prakruti assesment 
Ancient Science of Life  2012;32(Suppl 1):S72.
A new approach for Prakruti Assessment By Gradation method.
In Ayurveda, Charakacharya described Prakruti according to Gunas. Guruwadi twenty Gunas are also helpful in Chikitsa. Out of these 20 Gunas: Guru, Laghu, Shita, Ushna, Ruksha and Snigdha are more dominant in 6 Rasas; and these 6 Rasas plays an important role in Chikitsa and maintenance of Prakruti. Prakruti is formed by dominance of Dosha Gunas and diet taken by mother and her activity. The diet is composed of 6 types of Rasadravyas. The 6 Rasas are formed from the above 6 Gunas. Hence the Lakshanas due to these 6 Gunas has been given more importance in theassessment of Prakruti by gradation method.
Gradation method: Lakshanas of the Prakruti were classified into two groups: 1. Lakshana due above six Gunas were given 2 marks, 2. Lakshana due to all other Gunas were given 1 mark.
In Vata Prakruti: Lakshanas due to Ruksha, Laghu, and Shita Gunas were given 2 marks and others were given 1 mark. In Pitta Prakruti: Lakshanas due to Ushna, Laghu and Katu Gunas were given 2 marks and others were given 1 mark. In Kapha Prakruti: Lakshanas due to Snigdha, Shita, and Guru Gunas were given 2 marks and others were given 1 mark.
By Gradation method, Prakruti is assessed not only by Dosha but predominance of Gunas of an Individual Dosha. It is useful if there is predominance of same Dosha by percentage method. This helps to study Prakruti statistically.
PMCID: PMC3800953
6.  Effect of Pippalimula on Ama w.s.r. to Samavaya 
Ayu  2014;35(1):35-41.
Shad Karanas mentioned in Ayurveda are the means for attaining the state of Dhatusamyata. Samavaya is the sixth Karana among these and it provides the knowledge of relation between Dravya, Guna and Karma. This kind of knowledge becomes the basic tool in the field of diagnosis as well as in the selection of proper drug.
To assess the Samavaya relation between Ama and its Hetu and Lakshanas along with Practical evaluation of Samavaya by using Pippalimula on Ama.
Materials and Methods:
The study comprising of total 23 patients of Ama and divided into two groups. Pippalimula tablet (each of 500 mg, 2 tablets four times daily) was administered in Group A (n = 13) while Group B (n = 10) was treated with placebo tablet (each of 500 mg, 2 tablets four times daily) for the duration of 10 days.
After the completion of treatment, all the parameters of Group A showed statistically highly significant results, whereas in Group B some parameters showed significant results and others were insignificant.
The study specified the Karanatva of Samavaya as the Laghu, Ruksha and Ushna Gunas which were present Samavayatvena in Pippalimula, and were absent in placebo.
PMCID: PMC4213965  PMID: 25364197
Ama; Pippalimula; Samavaya; Shadkarana
7.  Evaluation of diet and life style in the etiopathogenesis of Urdhwaga Amlapitta (non-ulcer dyspepsia) 
Ayu  2013;34(4):352-355.
For a long time, infectious (communicable) diseases were the biggest killer diseases globally. But now, the trend is changing toward increased prevalence of chronic diseases with causative factors mostly related to diet and lifestyle. Among them, Urdhwaga Amlapitta (non-ulcer dyspepsia), a gastrointestinal tract (GIT) disorder, has acquired majority of the share with causative factors like improper diet and habits, stress, spicy irritant food, oily foods, bakery products, etc., A survey study was conducted on 138 patients, irrespective of sex, religion, etc., who had presented with the clinical symptoms of Urdhwaga Amlapitta and attended the OPD of Department of Basic Principles, at I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar, between February 2009 and June 2010. Information on demography, dietary intake, and lifestyle factors was collected by standard questionnaires. The data revealed that majority of the patients indulged in faulty dietary habits like excess Katu Ahara Sevana (99.3%), Amla Ahara (95.65%), Guru Ahara (90.57%), Snigdha Ahara (86.23%), Viruddha (81.88%), Abhishyandi Ahara (81.88%), Atiushna Ahara (73.9%), Vidahi (51.44%), Pistanna (47.10%), etc., and the data on lifestyle revealed that majority of the patients indulged in Diwasvapna (89.85%), Antarodaka Paanam (81.88%), Chinta (79.71%), etc., This survey study upholds the novel concept of diet and lifestyle of Ayurveda. The data reflects that dietary patterns, lifestyle choices, and physical activities play an important role in the etiopathogenesis of Urdhwaga Amlapitta, and it is important for patients to have access to diet and lifestyle modifications. Currently, research in this area is minimal.
PMCID: PMC3968695  PMID: 24695749
Diet; life style; non ulcer dyspepsia; Urdhwaga Amlapitta
8.  Clinical evaluation of the efficacy of Dashanga Kwatha Ghana Vati in the management of Urdhwaga Amlapitta (Non-ulcer dyspepsia) 
Ayu  2012;33(2):219-223.
A study has been designed to evaluate the effectiveness of Dashanga Kwatha Ghana Vati in Urdhwaga Amlapitta (non-ulcer Dyspepsia). Randomized single blind, placebo controlled study was conducted in 138 patients attending O.P.D. of department of Basic Principles, I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar, and grouped into two. Both the groups consumed two tablets of either Dashanga Kwatha Ghana Vati or placebo, twice daily after food for a period of eight weeks. The patients were followed upto four weeks, 110 patients had completed the treatment and no adverse effects were reported during the treatment. Both groups had improved in the clinical symptoms and overall statistical significance was observed in the differences of scores between the two groups.
PMCID: PMC3611627  PMID: 23559793
Dashanga Kwatha Ghana Vati; non-ulcer dyspepsia; Urdhwaga Amlapitta
9.  PA01.65. Comparative study of kumari swarasa and kanyasara in management of kashtartava 
Ancient Science of Life  2012;32(Suppl 1):S115.
Kumari (Aloe barbadensis Mill.) is a miracle plant. In Ayurvedic Texts Kumari has raspanchaka as: Guna Guru, Snigdha, Pichhial; Rasa Tikta, Madhur; Vipaka Katu; Veerya Sheeta whereas Kanyasara has rasa panchaka as: Guna Laghu Ruksha, Teekshna; Rasa Katu; Veerya Ushna ; Vipaka Katu. On the basis of different raspanchaka comparative study has been done to analyse its effect in the management of Kashtartava.
30 patients of age group 15 35 were selected randomly, group 1 (15 patients) was given Kumari Swarasa 10 ml BD and group 2 (15 patients) was given Kanyasara Vati 250 mg BD for10 days before expected commencement of Menstrual cycle for 3 menstrual cycles.
Group 2 showed 25.11% more relief than group I which is significant at p<0.05. (t =3.283). Kanyasara having Katu rasa and Katu vipaka which has predominance of Vayu + Agni mahaboota. It has Strotasa shodhna & Kaphahara activities due to which it removes clots, increases flow of menstrual blood and due to Ushna Virya it improves rhythmic contractions of uterus.
In-group 1) 5 were improved it was effective in premenstrual symptoms like anorexia etc. In group 2) 5 Patients were markedly improved, 9 moderately improved in over all symptoms. Hence Kanyasara is best line of treatment in Kashtartava.
PMCID: PMC3800869
10.  PA03.19. Clinical study on the effect of Moorchita Tila Taila Shamana Sneha and Navaka Guggulu in Hyperlipidemia – A comparative study 
Ancient Science of Life  2013;32(Suppl 2):S88.
Hyperlipidemia is a disorder which is identified as a potential risk factor for multitudes of diseases like cardiovascular diseases, metabolic syndrome and even hypertension. Hyperlipidemia is term used to denote raised serum levels of cholesterol or triglycerides or both. Though, there is no precise terminology for Hyperlipidemia mentioned in the Ayurvedic classics, A detailed study of Hyperlipidemia reveals its similarity to Asthayi Medo Dhatu Vriddhi on the basis of its Pathophysiology.
For Group A Moorchita Tila Taila 15ml twice daily as Shamana Sneha with Ushna jala for 30 days. For Group B Navaka Guggulu in Tablet form 500mg, 1 tab thrice daily for 30 days.
Both the groups A and B showed reduction in serum Total Cholesterol, Triglycerides, LDL–C and VLDL–C and Group A showed slight increase in HDL levels.
Shamananga snehapana can be safely carried out in patients of Hyperlipidemia. Comparing both the groups, Group A treated with Moorchita Tila Taila Shamana Sneha showed better results in reducing serum lipid values than Group B treated with Navaka Guggulu
PMCID: PMC4147563
11.  Standardization and quality control parameters of Dashanga Kwatha ghana tablet: An Ayurvedic formulation 
Herbal medicines have a long therapeutic history and are still serving many of the health needs of a large population of the world. However, the quality control and quality assurance still remains a challenge because of the high variability of chemical components involved. Herbal drugs, singularly and in combinations, contain numerous compounds in complex matrices in which no single active constituent is responsible for the overall efficacy. This creates a challenge in establishing quality control standards and standardization of finished herbal drugs. Many preparations have been mentioned in Ayurvedic text books for the treatment of Urdhwaga Amlapitta (non-ulcer dyspepsia). Dashanga Kwatha is one such known formulation. In this study, Dashanga Kwatha was converted into tablet form to increase the shelf life, make it easy to dispense, for dose fixation, etc. The Dashanga Kwatha Ghana tablet was subjected to organoleptic analysis, phytochemical analysis, and qualitative analysis to detect the presence of various functional groups, and to high performance thin layer chromatography (HPTLC) examination by optimizing the solvent systems. The investigation revealed the presence of tannins, mucilage, ascorbic acid, alkaloids, saponins, glycosides, flavonoids and carbohydrates mainly.
PMCID: PMC3157108  PMID: 21897642
Dashanga Kwatha; decoction; quality control; standardization; tablet
12.  PA01.62. Mukta-sukti bhasma; nectar for acid peptic disorders, w.s.r to its anti-ulcer activity - an experimental study 
Ancient Science of Life  2012;32(Suppl 1):S112.
Mukta Shukti (Pearl oyster shell); a sudha varga dravya, attains better therapeutic properties with proper sodhana and marana processes. It is indicated in Amlapitta, Parinamashoola and Annadravashoola. Acharya Susruta mentioned; Amla is the property of Vidagdha Pitta. The term Amlapitta may be correlated with Acid reflux syndrome which comprises of various types of Gastro esophageal reflux diseases like Gastritis, Peptic ulcer etc. A peptic ulcer is a sore on the lining of the stomach or duodenum, the beginning of the small intestine. A bacterium called Helicobacter pylori is a major cause of peptic ulcers. An attempt was made in this regard to establish standards to assure quality and to assess antiulcer activity of Mukta Sukti Bhasma.
Mukta sukti Bhasma prepared as per Rasatarangini and subjected to Atomic absorption spectroscopy (AAS) and X ray diffraction (XRD). Anti ulcer activity of Mukta sukti Bhasma in Albino rats by Aspirin induced gastric ulcer. Sucralfate as standard group and normal food water as control group used for the comparison.
Mukta sukti Bhasma showed highly significant Anti ulcer activity than control group. The alkaline pH and chemical components might have contributed by inhibiting secretions, neutralizing the acidity and reducing size of the ulcerative lesions. Presence of Calcium (Ca), Magnesium (Mg), Manganese (Mn), Iron (Fe), Potassium (K), Aluminum (Al), Copper (Cu), Sodium (Na) and Zinc (Zn) were detected in raw Mukta sukti and Mukta sukti Bhasma. X ray diffraction shown face centered Cubic, hexagonal, tetragonal and monoclinic crystal structures.
In aspirin induced model, the Mukta sukti Bhasma and standard group (Sucralfate) showed highly significant Anti ulcer activity than control group (food water). The Mukta sukti Bhasma showed highly significant Anti ulcer activity than standard group (Sucralfate) when compared. This experimental study has given scientific evidence for the claim in the ancient text regarding the Anti ulcer property of Mukta sukti Bhasma which gives scope for conducting clinical study.
PMCID: PMC3800866
13.  Conceptual and applied study of Snigdha and Ruksa Guna with special reference to Rasa-raktagata Sneha (hyperlipidemia) 
Ayu  2011;32(2):200-206.
Ayurveda as well as Philosophy accepted the Guna as the basic entity of the Sristi. The Maha Gunas, i.e., Sattva, Raja, and Tama are the prime energy, from where the universe evolves, along with human beings. Dravya and Guna both have a Samavayi relationship in which Gunas reside in Dravya and have a secondary place to it. Guna has multifold meanings according to its use, in social, cultural, philosophical, and literary fields. The concepts of Ayurveda are expressed with Gunas. Samanya and Visesa are usually expressed in terms of Gunas; the classification, description, and function of Dravyas depends upon Guna; Karmas are manifested forms of Guna and Samavaya is the eternal, intimate relation of Dravya and Guna. The principles like Triskandha (Hetu, linga, ousadhi) of Ayurveda also narrated by Gunas, Hetus are narrated in the terms of Guna; the Laksanas are the reflections in the status of Gunas of bodily elements, and Cikitsa is in the form of administration of Viparita Gunas. The increased elements are treated by opposite Guna. So if Ruksa Guna is increased then it is to be managed by Snigdha Guna and vice-versa. So diseases can be treated by applying the Gunas, and drugs for the required patient can be selected by applying these Gunas. In support of the above concept, a study on the persons of Rasa-raktagata Sneha (hyperlipidemia) has been carried out assuming that the condition is an increased state of Snigdha Guna and treatment is done using Ruksa property drugs. Patients were divided into two groups, i.e., treatment group (Ruksa Guna drugs) and control group (placebo). The results were assessed after 45 days with the help of a specially prepared pro forma. All the important hematological, biochemical, and urine investigations were done. According to subjective and objective criteria, significant results were found for Group A as compared to Group B.
PMCID: PMC3296341  PMID: 22408303
Ayurveda; Guna; hyperlipidemia; Rasa-raktagata Sneha; Ruksa Guna
Ancient Science of Life  1995;14(3):143-149.
A total of 36 patients of Amlapitta were selected for the clinical study. Vasa was given to 20 of them having hyperacidity and hyperchlorhydria. The patients were mainly of Urdhvaga Amlapitta. A symptomatic improvement was observed in the patients. Udgara and Vamana were considered as the presenting features of Amlapitta. A 60 ml syrup of dry leaves of Vasa (30 gm crude drug) was given to each patient in 4 divided doses for a duration of 6 weeks. Effect was assessed in terms of clinical symptomatology, free acid and total acid, in gastric juice.
PMCID: PMC3331233  PMID: 22556691
15.  Anti-inflammatory activity of Guduchi Ghana (aqueous extract of Tinospora Cordifolia Miers.) 
Ayu  2014;35(1):108-110.
Guduchi Ghana is one of the unique Ayuvedic classical preparation which is prepared from aqueous of extract of Guduchi (Tinospora cordifolia Miers.) stem. It is one of the frequently used drugs to treat the Madhumeha, Pandu, Kamala, Amlapitta, Grahani, Kustha, Jirna Jwara and Viswamjwara, Trishna, Shool, Yakritavikara, etc. Looking to these indications, in market most of the Pharma industries prepared Guduchi Ghana by applying the various extraction process.
To evaluate comparative anti-inflammatory activity of classically prepared and market sample of Guduchi Ghana.
Materials and Methods:
Both samples were evaluated for anti-inflammatory activity using carrageenan induced paw edema model in rats. Animals were divided in three groups, having six animals in each. Group A received test drug, Group B received market sample at a dose of 50 mg/kg orally, while Group C (control group) received tap water.
Reduction in edema was observed in Group A and B at 3 h interval by 33.06% and 11.71% respectively. Group A showed significant effects (P < 0.05) in comparison to control group.
These experimental results have shown anti-inflammatory activity of Guduchi Ghana.
PMCID: PMC4213960  PMID: 25364210
Anti-inflammatory activity; aqueous extract; carrageenan; Ghana Kalpana; Guduchi; Tinospora cordifolia
16.  PA01.69. Immunological and virological effect of amrita tablate in human immunodeficiency virus positive patients 
Ancient Science of Life  2012;32(Suppl 1):S119.
To assess the safety and efficacy of Amrita tablets in human immunodeficiency virus positive patients.
The randomized double blind placebo controlled trial carried out 40 HIV positive patients at Ayurvedic Drug Research Institute Motihari Bihar, with permission from Institutional Ethic Committee for achieve the purpose. Out of 40 HIV patients 30 were male and 10 patients of female. The HIV positive patients were randomly assigned to three groups A, B and C. Group A received Amrita tablet. Group B received Amritasava and group C received Placebo. The doses of Amrita tablet, two tabs. And Amritasava 10ml with one cup water twice daily for six months. The hematological investigation was repeated at the end of the study.
In study participants, HIV was more common in the 15 30 year's age group. Half of the enrolled patients where from the age group 42% from 30 40 years and 8% from 40 50 age group. It was observed the end of trial period of amrita tablet was marked increase in the number of CD4count and viral load reduced<300 copies/ml. It was also found gradual reduction of clinical feature of early symptomatic stage of HIV disease. Among the participants received Amritasava there was moderate increase in the number of CD4 count, but there was no difference in viral load. Participants was received placebo there was no differences in CD4 count before the six months.
Amrita tab. is an ideal herbal formulation. It contain mainly standardchemically defined Asava of Amrita (Tinospora cardifolia) ashwagandha (Withania somnifera) and yasthimadhu (Glycyrrhiza glabra). It increases in number of CD4 count and reduce viral load. It is safe and no adverse toxic effect on long therapy. Now it is necessary to evaluate the physiological activity, pharmacological property toxicity and determination of structure of amrita tab. To antiretroviral classes of drug for used in the health care systems of countries with in the Region and elsewhere in the world.
PMCID: PMC3800873
17.  A clinical study of Haritaki and Saindhava Lavana in Kaphaja Kasa with special reference to Samyoga Guna 
Ayu  2011;32(3):357-360.
In clinical practice, Guna which are to be with Bhisak are mainly the Paradi Gunas which can also be called as Miscellaneous Gunas. As rightly quoted by Acarya Caraka, for getting success in the treatment Paradi Gunas are the best. The Sutra quotes “Sidhyupaya Cikitsayam” which means that Cikitsa i. e. Dhatusamya will be done mainly with the help of Paradi Gunas. Thus in this study an attempt was made to know the comparative effect of Haritaki and Saindhava lavana alone and Samyukta effect in Kaphaja Kasa. Three groups were made for proper evaluation of the therapy. In Group-A Haritaki Tablet 2 gm/ twice a day (500 mg tablet × 4), In Group-B Saindava Lavana Curna 2 gm/ twice a day and in Group-C Haritaki + Saindhava lavana Tablet 4 gm/twice a day (500 mg tablet × 8) was given. Results were assessed after 7 days with the help of a specially prepared proforma. The hematological, Urine and Stool investigations were carried out. In subjective and objective criterias, significant results were found in Group-C as compared to Group-A and Group-B. Based on the results, it can be concluded that the combined (Samyoga) effect of Haritaki and Saindhava lavana is much efficient than the single drug therapy.
PMCID: PMC3326882  PMID: 22736910
Guna; Haritaki; Paradi Guna; Saindhava lavana; Samyoga
18.  Medohara and Lekhaniya dravyas (anti-obesity and hypolipidemic drugs) in Ayurvedic classics: A critical review 
Ayu  2013;34(1):11-16.
Santarpanottha Vikaras (diseases due to excessive nutrition) are increasing during current times. Medodushti (disorders of fat metabolism) serves as one of the important etiological factor in most of these disorders including Ischemic Heart Disease (IHD). IHD is identified as one of the leading cause of morbidity and mortality worldwide in both developing and developed countries. Retention and deposition of serum lipids resulting in decreased flow of blood in coronary arteries being the underlying cause. Conventional and herbal drugs are being used to lower levels of serum cholesterol to prevent this menace. In this regard, an attempt has been made to critically review the Medohara and Lekhaniya (Anti-obesity and Hypolipidemic) drugs mentioned in Ganas (group of drugs) of Ayurvedic classical texts which may abet our understanding of prevention and management of conditions like Dyslipidemia and its complications. Administration of drugs possessing Tikta Rasa (bitter taste), Ushna Veerya (hot in potency), Laghu and Ruksha Guna (light and dry qualities), Katu Vipaka and Vata Kaphahara actions were noted during the analysis.
PMCID: PMC3764867  PMID: 24049399
Dyslipidemia; Lekhana; Medohara; obesity; herbs
19.  Role of Virechana Karma in cure and prevention of recurrence of Vicharchika (Eczema) 
Ayu  2012;33(4):505-510.
Mandip and Chandola reported that administration of Rasayana (Guduchi and Bhringaraja) after Koshtha Shuddhi with Aragvadha Hima and simultaneous giving of Shirishadi decoction orally and applying of Snuhyadi Lepa externally provided complete remission to 22.6% patients of Vicharchika (Eczema) and checked the recurrences of the disease in the 89.5% patients. As in this group, cure rate was not up to the expectation; therefore, it was thought desirable to see whether performing of Virechana Karma instead of Koshtha Shuddhi prior to the administration of the above drugs enhances the cure rate for the Vicharchika (Eczema) patients. For the present study, 39 patients of Vicharchika (Eczema) were registered, of which 32 patients completed the full course of the treatment. These patients were given Virechana after preparing with the proper internal Snehana, Abhyanga, and Svedana as per classical method. After the Samsarjana Krama, they were administered the Shirishadi decoction and Guduchi-Bhringraja Rasayana powder orally with simultaneous local application of Snuhyadi Lepa on the eczematous lesions. The results of this study showed that when Virechana Karma was performed prior to the administration of Guduchi-Bhringaraja Rasayana and Shirishadi decoction orally and SnuhyadiLepa externally, it not only increased the cure rate to 81.3% in the patients of Vicharchika (Eczema) but also checked the recurrences to great extent as only negligible number of the patients reported the recurrence.
PMCID: PMC3665194  PMID: 23723667
Eczema; Koshtha Shuddhi; Rasayana; Vicharchika; Virechana Karma
20.  The efficacy and safety of Baoji Tablets for treating common cold with summer-heat and dampness syndrome: study protocol for a randomized controlled trial 
Trials  2013;14:440.
Despite the high incidence and the economic impact of the common cold, there are still no effective therapeutic options available. Although traditional Chinese medicine (TCM) is widely used in China to treat the common cold, there is still a lack of high-quality clinical trials. This article sets forth the protocol for a high-quality trial of a new TCM drug, Baoji Tablets, which is designed to treat the common cold with summer-heat and dampness syndrome (CCSDS). The trial is evaluating both the efficacy and safety of Baoji Tablets.
This study is designed as a multicenter, phase II, parallel-group, double-blind, double-dummy, randomized and placebo-controlled trial. A total of 288 patients will be recruited from four centers. The new tablets group are administered Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g. The old pills group are administered dummy Baoji Tablets 0.9 g and Baoji Pills 3.7 g. The placebo control group are administered dummy Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g. All drugs are taken three times daily for 3 days. The primary outcome is the duration of all symptoms. Secondary outcomes include the duration of primary and secondary symptoms, changes in primary and secondary symptom scores and cumulative symptom score at day 4, as well as an evaluation of treatment efficacy.
This is the first multicenter, double-blind, double-dummy, randomized and placebo-controlled trial designated to treat CCSDS in an adult population from China. It will establish the basis for a scientific and objective assessment of the efficacy and safety of Baoji Tablets for treating CCSDS, and provide evidence for a phase III clinical trial.
Trial registration
This study is registered with the Chinese Clinical Trial Registry. The registration number is ChiCTR-TRC-13003197.
PMCID: PMC3878040  PMID: 24359521
Common cold; Summer-heat and dampness syndrome; Baoji Tablets; Traditional Chinese medicine; Randomized controlled trial
21.  OA01.12. A clinical study of efficacy of Vyoshadi gutika and Pippalayadi churna avapida nasya in the management of Pratishyaya 
Ancient Science of Life  2012;32(Suppl 1):S12.
Pratishyay basically is a Vat-kaphaj disorder arising from accumulation of vitiated Vat along with kaph-pitta-rakta in uttamang (shirh pradesh) and comparable to Rhinitis which describes a group of symptoms including runny nose, stuffiness, sneezing usually due to common cold, environmental irritants and immunodeficiency. This study aim to do 1. Evaluation of effectiveness of Vyoshadi gutika (samshaman therapy) and Pippalayadi churna Avapida nasya (samshodhan therapy) in the management of pratishyay, 2. Statistical assessment of data post treatment.
60 patients of Pratishyay aged between 16-60 years of age of both sexes complaining of Rhinorrhoea/ nasal block, sneezing, heaviness of head, anosmia were selected randomly and assigned for clinical study were divided into 2 groups. Group A consisting of 30 patients had internal administration of Vyoshadi gutika in a dose of 2 tablets QID (each tab. 375 mg) with lukewarm water for 30 days. Group B-30 patients took Vyoshadi gutika along with Pippalayadi churna Avapida nasya (6 drops in each nostril early morning) for duration of 21 days. All patients were advised to attend 15 days Intercal regularly for 3 months for assessment of disease through subjective and objective parameters.
60% patients (18 no.) of Group B while 47% patients (14 no.) Group A responded satisfactorily with maximum improvement (more than 76% symptomatic improvement). Similarly, Moderate improvement (between 51-75%) was seen in 47 patients of Group A and 37% of Group B while mild improvement in 10% and 3% patients of Group A and B respectively. No untoward adverse effects were seen in any patients.
It can be concluded that on the basis of Practical, Therapeutic and Statistical analysis, patients of both groups got satisfactory improvement. Besides, patients treated with both Samshodhan Nasya therapy and Samshaman Vyoshadi Gutika therapy comparatively got better results.
PMCID: PMC3800874
22.  Role of Rasayana in Cure and Prevention of Recurrence of Vicharchika (Eczema) 
Ayu  2010;31(1):33-39.
Generally, skin diseases run a chronic course and the recurrence is very common. Mandip and Chandola (2009) reported that Shirishadi Decoction administered orally and simultaneously Snuhyadi Lepa applied externally to the patients of Vicharchika (Eczema) provided complete remission to 18.2% patients, marked improvement to 42.4% patients and moderate improvement to 36.4% patients but the recurrence rate was very high i.e. 80%. Charaka, in the context of the treatment of Apasmara mentions that in all the chronic diseases, Rasayana drugs should be prescribed. As eczema is a chronic disease and its recurrences are very common, therefore, it was thought desirable to evaluate the role of the Rasayana drugs in the cure and prevention of the recurrence of Vicharchika (Eczema). In this study, total 38 patients of Vicharchika (Eczema) were registered, among which 31 patients completed the full course of treatment. These patients were first subjected to Koshtha Shuddhi done with Aragvadha (Cassia fistula) Hima administered orally at bedtime for initial eight days. Thereafter 30 ml of Shirishadi Decoction and 6 gm of Guduchi (Tinospora cardifolia) and Bhringaraja (Eclipta alba) powder was given with Ghrita. Both the drugs were given twice daily after meals orally. Simultaneously, Snuhyadi Lepa was applied on the eczematous lesions. Results of the study showed that addition of Rasayana drugs provided complete remission to 22.6% and checked the recurrence of the disease in the 89.5% patients of Vicharchika (Eczema).
PMCID: PMC3215319  PMID: 22131682
Vicharchika; Rasayana; Koshtha Shuddhi; Shirishadi Decoction; Snuhyadi Lepa; Guduchi- Bhringaraja Rasayana; Eczema; Recurrence
23.  PA01.78. Ayurvedic diet in pregnancy 
Ancient Science of Life  2012;32(Suppl 1):S128.
The fast changing life style of the modern era has caused increase in the pregnancy complications, anamolies etc. due to the change in the diet of pregnant women. Ayurveda has focused on this concept & have explained it very effectively. The diet of pregnant woman is not only explained according to the need of the mother but also by the fetus, which is advised month wise (masanumasik patya). Thus, it is very necessary to promote the pregnant women to take proper diet i.e. masanumasik patya which will lead to healthly & safe motherhood along with its outcome.
Masanumasik patya of Ayurveda, as the name suggest, is advised according to the month & by the need of fetal development. During pregnancy. Various symptoms are faced by woman like in first trimester, nausea, vomiting is seen very comman. Thus, patya advised is madhura, shita, drava (liquid), which will prevent dehydration & supply required nourishment. In second trimester, development of muscles, organs occurs, so the diet rich in proteins is advised. In third trimester retention of water, constipation is seen & finally preparation of genital tract for delivery is needed. So patyas prescribed are diuretics. Mild laxatives and basti, which will smoothen genital tract. According to Ayurvedic diets, the junk & fast food which is prevalent now is not benificial for mother & fetus is also described.
As mentioned above, the diet of pregnant woman according to month is proved to se helpful for mother & fetus. Also the present diet substances causes complication. Thus Masanumasik patya is the need of the hour.
It is therefore clear that the diet of pregnant woman according to Ayurveda will prevent many complications of pregnancy, which will lead to healthy pregnancy & healthy fetus & finally good outcome.
PMCID: PMC3800883
24.  JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial 
Trials  2010;11:27.
Pre-diabetes is a growing health concern where a large percentage of these patients develop full type 2 diabetes. Effective interventions on pre-diabetes can prevent or delay the occurrence or development of diabetes. Pharmaco-dynamics and pre-clinical of JinQi-Jiangtang tablets (JQJT) suggest that it could be benefit for pre-diabetes.
Randomized controlled trial (RCT) is implemented in this study. The study term is 24 months (12 months for intervention and 12 months for follow up). Participants are recruited from four cities of China: Beijing, Tianjin, Xi'an and Nanning. Four hundred participants are randomized to treatment group (JQJT tablets) and control group (Placebo); two hundred participants each. People being included in this study must have been diagnosed as pre-diabetes via western medicine criteria and traditional Chinese medicine (TCM) criteria. The end-point indexes include: incidence of diabetes mellitus and reversion rate. Primary outcome indexes include: oral glucose tolerance test; insulin releasing test; glycosylated hemoglobin (HA1c). Secondary outcome indexes include: score of the Short Form 36 Health Survey Questionnaire (SF-36); score of TCM symptoms; blood lipid test. Indexes of safety include: general medical examination; blood and urine regular test; electrocardiogram (ECG), liver function (ALT) and renal function (BUN, Creatinine) test; record of adverse event, such as headache, faint, etc. Qualitative control will be implemented and a number of standard operating processes (SOPs) will be formed throughout the study: laboratory quality control measures; compliance control for researchers and participants; researcher training before study; supervision; investigational drug management and others.
The aim of this study is to evaluate the effectiveness and safety of JinQi JiangTang (JQJT) tablets for the treatment of patients with pre-diabetes.
Trial registration
Chinese clinical trials register ChiCTR-TRC-00000401
PMCID: PMC2842259  PMID: 20214831
25.  OA03.08. Clinical study of shaliparni ksheer paka in the management of hypertension 
Ancient Science of Life  2013;32(Suppl 2):S31.
Hypertension is reported as the third ranked factor for disability adjusted life years and is one of the primary risk factors for heart diseases and stroke, the leading cause of death worldwide. Overall, approximately 20% of world's adults are estimated to have hypertension. However, there is no definite term given in Ayurveda which clearly represents the disease but many scholars have tried to suggest some appropriate names to hypertension on the basis of their research and pathogenesis of the disease like Dhamani paripurnata, Uccharaktachapa, Siragata vata, Raktagata vata, Avritta vata roga, Rakta sampeedana etc. For its treatment, use of lifelong administration of antihypertensive drugs leads to many side effects. Hence, the present study has been under taken with the hope of searching out a better, safer, low economic remedy for the disease by evaluating the therapeutic effects of Shaliparni ksheer Paka and comparing it with the effects of allopathic drug Tab. ‘Telmisartan’ in the management of hypertension.
Clinical study was carried out on 60 patients of hypertension, selected randomly from OPD/IPD of Arogyashala, N.I.A., Jaipur which were categorized into two groups. 30 Patients of Group A were treated with control drug Telmisartan – 20mg or 40 mg, OD and 30 patients of Group B were treated with Trial drug Shaliparni Ksheer Paka, (Ch. Chi. 28/9), 150 ml, twice a day for 45 days. Results before treatment and after treatment was compared and analyzed statistically.
The study reveals that Patients in Group A showed more improvement in reducing the blood pressure whereas that of Group B showed more improvement on the symptoms produced in hypertension and the cholesterol level which was statistically significant.
The drug Shaliparni Ksheer Paka can be used efficiently in the management of hypertension.
PMCID: PMC4147501

Results 1-25 (764634)